{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:05:29Z","timestamp":1793415929748,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell'Istruzione, dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015694","name":"Fondazione Cassa di Risparmio di Firenze","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Pirfenidone is a small drug with marked antifibrotic activity approved for the treatment of Idiopathic pulmonary fibrosis. Recently, its peculiar pharmacological profile has attracted attention for its potential therapeutic benefit for extra-pulmonary disorders characterized by pathological fibrosis, such as kidney, liver, and cardiac failure. A major pitfall of pirfenidone is the lack of consistent understanding of its mechanism of action, regardless of the target. In addition to the increasing attention to the role of inflammation and its mediators in several processes, a better knowledge of the variety of fibroblasts' population, of signals controlling their activation and trans-differentiation, and of crosstalk with other cell resident and non-resident cell types is needed for prevention, treatment and possibly reverse of fibrosis. This review will focus on pirfenidone's pharmacological profile and its effects on cardiac fibroblasts.<\/jats:p>","DOI":"10.3389\/fcvm.2022.751499","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T04:31:17Z","timestamp":1663648277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacological basis of the antifibrotic effects of pirfenidone: Mechanistic insights from cardiac in-vitro and in-vivo models"],"prefix":"10.3389","volume":"9","author":[{"given":"Laura","family":"Sartiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Bartolucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pallecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Cerbai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"B1","unstructured":"2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0091270007304104","article-title":"Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers","volume":"47","author":"Shi","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.pupt.2009.03.003","article-title":"Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults","volume":"22","author":"Rubino","year":"2009","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B4","unstructured":"FDAU,. Esbriet (pirfenidone) capsules US prescribing information.\n          2021"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1755-1536-3-16","article-title":"The multifaceted role of pirfenidone and its novel targets","volume":"3","author":"Mac\u00edas-Barrag\u00e1n","year":"2010","journal-title":"Fibrogenesis Tissue Repair."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7340641","DOI":"10.1155\/2016\/7340641","article-title":"Topical administration of pirfenidone increases healing of chronic diabetic foot ulcers: a randomized crossover study","volume":"2016","author":"Janka-Zires","year":"2016","journal-title":"J Diabetes Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"678530","DOI":"10.3389\/fcvm.2021.678530","article-title":"Rationale for the use of pirfenidone in heart failure with preserved ejection fraction","volume":"8","author":"Graziani","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B8","first-page":"1448","article-title":"High-resolution transcriptomic profiling of the heart during chronic stress reveals cellular drivers of cardiac fibrosis and hypertrophy","volume-title":"Circulation.","author":"McLellan","year":"2020"},{"key":"B9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/gene.20162","article-title":"In vivo genetic ablation by Cre-mediated expression of diphtheria toxin fragment A.","volume":"43","author":"Ivanova","year":"2005","journal-title":"Genesis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: Therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrcardio.2017.57","article-title":"Redefining the identity of cardiac fibroblasts","volume":"14","author":"Tallquist","year":"2017","journal-title":"Nature Rev Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41569-018-0086-9","article-title":"The deployment of cell lineages that form the mammalian heart","volume":"15","author":"Meilhac","year":"2018","journal-title":"Nat Rev Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00395-008-0739-7","article-title":"Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction","volume":"103","author":"Frantz","year":"2008","journal-title":"Basic Res Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/CIRCRESAHA.116.305381","article-title":"Getting to the heart of the matter: new insights into cardiac fibrosis","volume":"116","year":"2015","journal-title":"Circ Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e28134","DOI":"10.1371\/journal.pone.0028134","article-title":"In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion.","volume":"6","author":"Shi","year":"2011","journal-title":"PLoS ONE"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/dvdy.22280","article-title":"Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts","volume":"239","author":"Santiago","year":"2010","journal-title":"Dev Dynam."},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49285-9","article-title":"An improved method of maintaining primary murine cardiac fibroblasts in two-dimensional cell culture","volume-title":"Scientific Rep","author":"Landry","year":"2019"},{"key":"B18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/CIRCRESAHA.119.315491","article-title":"Generation of quiescent cardiac fibroblasts from human induced pluripotent stem cells for in vitro modeling of cardiac fibrosis","volume":"125","author":"Zhang","year":"2019","journal-title":"Circ Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/7651_2020_300","article-title":"Generation of quiescent cardiac fibroblasts derived from human induced pluripotent stem cells","volume":"2454","author":"Zhang","year":"2020","journal-title":"Methods Mol Biol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"102420","DOI":"10.1016\/j.scr.2021.102420","article-title":"Cardiac fibrosis models using human induced pluripotent stem cell-derived cardiac tissues allow anti-fibrotic drug screening in vitro","volume":"54","author":"Iseoka","year":"2021","journal-title":"Stem Cell Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e05279","DOI":"10.1016\/j.heliyon.2020.e05279","article-title":"Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis","volume":"6","author":"Barranco-Gardu\u00f1o","year":"2020","journal-title":"Heliyon."},{"key":"B22","doi-asserted-by":"publisher","first-page":"119741","DOI":"10.1016\/j.biomaterials.2019.119741","article-title":"Human cardiac fibrosis-on-a-chip model recapitulates disease hallmarks and can serve as a platform for drug testing","volume":"233","author":"Mastikhina","year":"2020","journal-title":"Biomaterials."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis-a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000369680","article-title":"Rapamycin attenuates aldosterone-induced tubulointerstitial inflammation and fibrosis","volume":"35","author":"Wang","year":"2015","journal-title":"Cell Physiol Biochem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.devcel.2012.08.017","article-title":"A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo","volume":"23","author":"Davis","year":"2012","journal-title":"Dev cell."},{"key":"B26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.4161\/chan.24328","article-title":"A TRP to cardiac fibroblast differentiation","volume":"7","author":"Thodeti","year":"2013","journal-title":"Channels."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.3390\/ijms20194912","article-title":"Angiotensin-ii drives human satellite cells toward hypertrophy and myofibroblast trans-differentiation by two independent pathways","volume":"20","author":"Laurino","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/cells10050990","article-title":"Channelling the force to reprogram the matrix: mechanosensitive ion channels in cardiac fibroblasts","volume":"10","author":"Stewart","year":"2021","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","first-page":"H512","DOI":"10.1152\/ajpheart.00137.2015","article-title":"Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts","volume":"309","author":"Yamagami","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jacc.2007.09.064","article-title":"Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation","volume":"51","author":"Burstein","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.106.624320","article-title":"Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure","volume":"114","author":"Lee","year":"2006","journal-title":"Circulation."},{"key":"B32","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/cvr\/cvt074","article-title":"Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-\u03b21","volume":"99","author":"Rahmutula","year":"2013","journal-title":"Cardiovasc Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1161\/01.RES.0000187457.24338.3D","article-title":"NAD(P)H oxidase 4 mediates transforming growth factor-\u03b21-induced differentiation of cardiac fibroblasts into myofibroblasts","volume":"97","author":"Cucoranu","year":"2005","journal-title":"Circ Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"105176","DOI":"10.1016\/j.phrs.2020.105176","article-title":"Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy","volume":"160","author":"Santini","year":"2020","journal-title":"Pharmacol Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.yjmcc.2007.01.009","article-title":"NADPH oxidase-dependent redox signaling in human heart failure: relationship between the left and right ventricle","volume":"42","author":"Nediani","year":"2007","journal-title":"J Mol Cell Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1089\/ars.2010.3198","article-title":"Nitric oxide\/reactive oxygen species generation and nitroso\/redox imbalance in heart failure: from molecular mechanisms to therapeutic implications","volume":"14","author":"Nediani","year":"2011","journal-title":"Antioxid Redox Signal."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox9111064","article-title":"Effects of pirfenidone and nintedanib on markers of systemic oxidative stress and inflammation in patients with idiopathic pulmonary fibrosis: a preliminary report","volume":"9","author":"Fois","year":"2020","journal-title":"Antioxidants."},{"key":"B38","doi-asserted-by":"publisher","first-page":"854314","DOI":"10.3389\/fcvm.2022.854314","article-title":"Pirfenidone has anti-fibrotic effects in a tissue-engineered model of human cardiac fibrosis","volume":"9","author":"Bracco Gartner","year":"2022","journal-title":"Front Cardiovasc Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"104694","DOI":"10.1016\/j.phrs.2020.104694","article-title":"Pirfenidone is a cardioprotective drug: MECHANISMS of action and preclinical evidence","volume":"155","author":"Aimo","year":"2020","journal-title":"Pharmacol Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jacc.2017.05.040","article-title":"Cell-specific pathways supporting persistent fibrosis in heart failure","volume":"70","author":"Farris","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B41","article-title":"Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy","volume-title":"Circulation","author":"Coppini","year":"2017"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.hrthm.2010.04.030","article-title":"Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias","volume":"7","author":"Nguyen","year":"2010","journal-title":"Heart Rhythm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/cvr\/cvx163","article-title":"Electrical coupling between ventricular myocytes and myofibroblasts in the infarcted mouse heart","volume":"114","author":"Rubart","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8879","DOI":"10.1038\/s41598-019-45078-2","article-title":"Myofibroblast modulation of cardiac myocyte structure and function","volume":"9","author":"Nagaraju","year":"2019","journal-title":"Sci Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/j.jacc.2019.02.049","article-title":"Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure","volume":"73","author":"Nagaraju","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.pharmtox.45.120403.095802","article-title":"The cardiac fibroblast: therapeutic target in myocardial remodeling and failure","volume":"45","author":"Brown","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41586-020-2797-4","article-title":"Cells of the adult human heart","volume":"588","author":"Litvinukov\u00e1","year":"2020","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10557-019-06876-y","article-title":"Pirfenidone in heart failure with preserved ejection fraction-rationale and design of the PIROUETTE trial","volume":"33","author":"Lewis","year":"2019","journal-title":"Cardiovasc Drugs Ther."},{"key":"B49","doi-asserted-by":"crossref","DOI":"10.1007\/s12265-022-10264-7","article-title":"Impact of myocardial fibrosis on cardiovascular structure, function and functional status in heart failure with preserved ejection fraction","volume-title":"J Cardiovasc Transl Res","author":"Lewis","year":"2022"},{"key":"B50","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10741-021-10175-w","article-title":"Pirfenidone as a novel cardiac protective treatment","volume":"27","author":"Aimo","year":"2022","journal-title":"Heart Fail Rev."},{"key":"B51","article-title":"Preclinical metabolic characterization of mefunidone, a novel anti-renal fibrosis drug","volume-title":"Life Sciences","author":"Luo","year":"2021"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.751499\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T04:31:28Z","timestamp":1663648288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.751499\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":51,"alternative-id":["10.3389\/fcvm.2022.751499"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.751499","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"article-number":"751499"}}